Comparison of safety profiles of DPP-4 inhibitors with SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252377Keywords:
DPP4 inhibitors, SGLT2 inhibitors, Adverse events, Safety comparison, Type II diabetes mellitusAbstract
In type 2 diabetes mellitus (T2DM), add-on therapy to metformin is often required. Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used, but differ in their safety profiles due to distinct mechanisms of action. This study aimed to systematically review and compare the safety outcomes of SGLT2 versus DPP-4 inhibitors in patients receiving background metformin therapy. A systematic literature search was conducted in PubMed for studies published from 2006 onward. Randomized controlled trials and observational studies evaluating safety outcomes of SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) and DPP-4 inhibitors (sitagliptin, teneligliptin, vildagliptin) as add-on to metformin were included. Data on adverse events (AEs), serious adverse events (SAEs), and drug-related adverse events (DRAEs) were extracted and analyzed. Twenty studies met the inclusion criteria: 8 studies on SGLT2 inhibitors (n=946) and 12 on DPP-4 inhibitors (n=1903). The overall incidence of AEs was higher with DPP-4 inhibitors (66%) compared to SGLT2 inhibitors (34%), while DRAEs were comparable (12% vs. 11%). SGLT2 inhibitors were more often associated with genital and urinary tract infections, whereas DPP-4 inhibitors had higher rates of gastrointestinal disturbances and hypoglycemia. Rare events included dehydration and atrial flutter (SGLT2) and dyspepsia and hypertension (DPP-4). Notably, adverse events varied across individual agents within each class. Both SGLT2 and DPP-4 inhibitors demonstrate acceptable safety as add-on therapy to metformin. Given drug-specific adverse events, individualized therapy based on patient characteristics is essential. Further large-scale safety-focused studies are warranted.
Metrics
References
Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708. DOI: https://doi.org/10.1016/j.biopha.2020.110708
Magliano DJ, Boyko EJ. IDF diabetes atlas. International Diabetes Federation; 2022.
Azzam MM, Ibrahim AA, Abd El-Ghany MI. Factors affecting glycemic control among Egyptian people with diabetes attending primary health care facilities in Mansoura District. Egypt J Intern Med. 2021;33(1):1-10. DOI: https://doi.org/10.1186/s43162-021-00065-w
Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2023. Diabetes Care. 2023;46(supp):S140-57. DOI: https://doi.org/10.2337/dc23-S009
Lim SW, Jin JZ, Jin L, Jin J, Li C. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. Korean J Intern Med. 2015;30(6):759-70. DOI: https://doi.org/10.3904/kjim.2015.30.6.759
Kasina SVSK, Baradhi KM. Dipeptidyl peptidase iv (DPP IV) inhibitors. 2019.
Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - Focus on alogliptin. Drug Des Devel Ther. 2013;7:989-1001. DOI: https://doi.org/10.2147/DDDT.S37647
Gupta V, Kalra S. Choosing a Gliptin. Indian J Endocrinol Metab. 2011;15(4):298. DOI: https://doi.org/10.4103/2230-8210.85583
Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: An update. Curr Opin Nephrol Hypertens. 2020;29(2):190-8. DOI: https://doi.org/10.1097/MNH.0000000000000584
Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. StatPearls. 2022.
Scheen AJ. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacokinet. 2020;59(8):981-94. DOI: https://doi.org/10.1007/s40262-020-00885-z
Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021;2(12):2027-37. DOI: https://doi.org/10.34067/KID.0002772021
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Cochrane Handb Syst Rev Interv. 2019;1-694. DOI: https://doi.org/10.1002/9781119536604
Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-9. DOI: https://doi.org/10.2337/dc13-2105
Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16(1):84. DOI: https://doi.org/10.1186/s12933-017-0564-0
van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202-12. DOI: https://doi.org/10.1016/j.kint.2019.09.013
Rosenstock J, Perl S, Johnsson E, García-Sánchez R, Jacob S. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(9):2152-62. DOI: https://doi.org/10.1111/dom.13795
Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1. DOI: https://doi.org/10.1186/s12933-019-0977-z
Khan A, Khan IA, Abidi H, Ahmed M. Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population. Front Endocrinol (Lausanne). 2022;13:926633. DOI: https://doi.org/10.3389/fendo.2022.926633
Hao Z, Sun Y, Li G, Shen Y, Wen Y, Liu Y. Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. BMC Endocr Disord. 2022;22(1):37. DOI: https://doi.org/10.1186/s12902-022-00949-0
Han KA, Kim YH, Kim DM, Lee BW, Chon S, Sohn TS, et al. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial. Diabetes Metab J. 2023;47(6):796-807. DOI: https://doi.org/10.4093/dmj.2022.0315
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205. DOI: https://doi.org/10.1111/j.1463-1326.2006.00704.x
Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri. Diabetologia. 2013;56(7):1503-11. DOI: https://doi.org/10.1007/s00125-013-2905-1
Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A. Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. J Pharmacol Pharmacother. 2013;4(1):27-32. DOI: https://doi.org/10.4103/0976-500X.107656
Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab England. 2015;17:309-12. DOI: https://doi.org/10.1111/dom.12424
Al Omari M, Khader Y, Dauod AS, Beni Yonis OA, Khassawneh AHM. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. J drug Assess. 2016;5(1):29-33. DOI: https://doi.org/10.1080/21556660.2016.1252379
Goldenberg R, Gantz I, Andryuk PJ, O’Neill EA, Kaufman KD, Lai E, et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on. Diabetes Obes Metab. 2017;19(3):394-400. DOI: https://doi.org/10.1111/dom.12832
Hong SM, Park CY, Hwang DM, Han KA, Lee CB, Chung CH, et al. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension. Diabetes Obes Metab. 2017;19(5):654-63. DOI: https://doi.org/10.1111/dom.12870
Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017 Jul;19(7):979-88. DOI: https://doi.org/10.1111/dom.12908
Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, et al. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab. 2019;21(5):1128-35. DOI: https://doi.org/10.1111/dom.13626
Ji L, Li L, Ma J, Li X, Li D, Meng B, et al. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study. Endocrinol diabetes Metab. 2021;4(2):e00222. DOI: https://doi.org/10.1002/edm2.222
Kitazawa M, Katagiri T, Suzuki H, Matsunaga S, H Yamada M, Ikarashi T, et al. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study. Diabetes Obes Metab. 2021;23(3):811-21. DOI: https://doi.org/10.1111/dom.14288
Kawalec P, Mikrut A, Łopuch S. The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. Diabetes Metab Res Rev. 2014;30(4):269-83. DOI: https://doi.org/10.1002/dmrr.2494
Biyabani SAU, Patil N, Faisal SR. Efficacy and Safety Profile of SGLT-2 Inhibitors as Add-on Therapy in Patients with Type 2 Diabetes: A Comprehensive Review. RGUHS J Pharm Sci. 2024;14(4). DOI: https://doi.org/10.26463/rjps.14_4_7
Trivedi D. DPP-4 Inhibitors in Type 2 Diabetes Mellitus A Panoramic Review. Ann Clin Med Case Rep. 2023;11(12):1-7.
Downloads
Published
How to Cite
Issue
Section
